Cargando…

Immunological Adverse Events After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients

Autologous hematopoietic stem cell transplantation (aHSCT) represents an effective treatment for systemic sclerosis (SSc), but it also can cause immunological adverse events (iAEs). Therefore, we aimed to determine the frequency of iAEs [engraftment syndrome (ES) and secondary autoimmune disorder (s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strunz, Patrick-Pascal, Froehlich, Matthias, Gernert, Michael, Schwaneck, Eva Christina, Fleischer, Anna, Pecher, Ann-Christin, Tony, Hans-Peter, Henes, Joerg Christoph, Schmalzing, Marc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8447845/ https://www.ncbi.nlm.nih.gov/pubmed/34539659 http://dx.doi.org/10.3389/fimmu.2021.723349

Ejemplares similares

Immunosuppressive Therapy After Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis Patients—High Efficacy of Rituximab
por: Gernert, Michael, et al.
Publicado: (2022)

Low B cell counts as risk factor for infectious complications in systemic sclerosis after autologous hematopoietic stem cell transplantation
por: Gernert, Michael, et al.
Publicado: (2020)

Autologous Stem Cell Transplantation in Common Variable Immunodeficiency: A Case of Successful Treatment of Severe Refractory Autoimmune Encephalitis
por: Froehlich, Matthias, et al.
Publicado: (2020)

Case Report: Effectiveness of secukinumab in systemic sclerosis with early skin progress after autologous hematopoietic stem cell transplantation and end-stage kidney disease
por: Strunz, Patrick-Pascal, et al.
Publicado: (2023)

Autologous hematopoietic stem cell transplantation in systemic sclerosis induces long-lasting changes in B cell homeostasis toward an anti-inflammatory B cell cytokine pattern
por: Gernert, Michael, et al.
Publicado: (2019)

Lymphocyte subsets in the peripheral blood are disturbed in systemic sclerosis patients and can be changed by immunosuppressive medication
por: Gernert, Michael, et al.
Publicado: (2021)

Calprotectin (S100A8/S100A9) detects inflammatory activity in rheumatoid arthritis patients receiving tocilizumab therapy
por: Gernert, Michael, et al.
Publicado: (2022)

Apps in der Rheumatologie: Bedarf es einer App in der Therapie der axialen Spondyloarthritis?
por: Strunz, Patrick-Pascal, et al.
Publicado: (2021)

High Prevalence of Genital Human Papillomavirus Infection in Patients With Primary Immunodeficiencies
por: Gernert, Michael, et al.
Publicado: (2021)

Patient-reported outcomes provide evidence for increased depressive symptoms and increased mental impairment in giant cell arteritis
por: Froehlich, Matthias, et al.
Publicado: (2023)

Optimal management of ANCA-associated vasculitis before and during pregnancy: current perspectives
por: Pecher, Ann-Christin, et al.
Publicado: (2022)

Tocilizumab in Large Vessel Vasculitis – Different Routes of Administration
por: Schmalzing, Marc, et al.
Publicado: (2018)

Inhibition of effector B cells by ibrutinib in systemic sclerosis
por: Einhaus, Jakob, et al.
Publicado: (2020)

Functionally Active Antibodies to the Angiotensin II Type 1-Receptor Measured by a Luminometric Bioassay Do Not Correlate With Clinical Manifestations in Systemic Sclerosis: A Comparison With Antibodies to Vascular Receptors and Topoisomerase I Detected by ELISA
por: Bankamp, Lukas, et al.
Publicado: (2021)

Invariant natural killer T cells are functionally impaired in patients with systemic sclerosis
por: Pecher, Ann-Christin, et al.
Publicado: (2019)

Erdheim-Chester disease with Rosai-Dorfman-like lesions: treatment with methotrexate, anakinra and upadacitinib
por: Portegys, Jan, et al.
Publicado: (2023)

Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
por: Fröhlich, Matthias, et al.
Publicado: (2021)

Autologous Hematopoietic Stem Cell Transplantation for Treatment of Systemic Sclerosis
por: Del Papa, Nicoletta, et al.
Publicado: (2018)

Sexual dysfunction and depression in Behçet’s disease in comparison to healthy controls
por: Saur, Sebastian-Jonas, et al.
Publicado: (2021)

Higher Age (≥60 Years) Increases the Risk for Adverse Events during Autologous Hematopoietic Stem Cell Transplantation
por: Haubitz, Monika, et al.
Publicado: (2023)

Editorial: Stem cell transplantation in autoimmune diseases (AID)
por: Schmalzing, Marc, et al.
Publicado: (2023)

Autologous hematopoietic stem cell transplantation in progressive severe multiple sclerosis
por: Pandit, Awadh Kishor, et al.
Publicado: (2015)

Regenerating Immunotolerance in Multiple Sclerosis with Autologous Hematopoietic Stem Cell Transplant
por: Massey, Jennifer C., et al.
Publicado: (2018)

Life after Autologous Hematopoietic Stem Cell Transplantation for Systemic Sclerosis
por: Moraes, Daniela A, et al.
Publicado: (2021)

Autologous hematopoietic stem cell transplantation improves long-term survival—data from a national registry
por: Blank, Norbert, et al.
Publicado: (2022)

Induction of IL-9 in Peripheral Lymphocytes of Rheumatoid Arthritis Patients and Healthy Donors by Th17-Inducing Cytokine Conditions
por: Heim, Jana, et al.
Publicado: (2021)

Minimal disease activity is a stable measure of therapeutic response in psoriatic arthritis patients receiving treatment with adalimumab
por: Behrens, Frank, et al.
Publicado: (2018)

Does concomitant methotrexate confer clinical benefits in patients treated with prior biologic therapy? Analysis of data from a noninterventional study of rheumatoid arthritis patients initiating treatment with adalimumab
por: Schmalzing, Marc, et al.
Publicado: (2020)

Sustained improvement in work outcomes in employed patients with rheumatoid arthritis during 2 years of adalimumab therapy: an observational cohort study
por: Behrens, Frank, et al.
Publicado: (2020)

Use of a “critical difference” statistical criterion improves the predictive utility of the Health Assessment Questionnaire-Disability Index score in patients with rheumatoid arthritis
por: Behrens, Frank, et al.
Publicado: (2019)

Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis
por: Casanova, Bonaventura, et al.
Publicado: (2017)

Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis
por: Helbig, Grzegorz, et al.
Publicado: (2017)

Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents
por: Gavriilaki, Maria, et al.
Publicado: (2019)

Intensive immunosuppression followed by autologous hematopoietic stem cell transplantation for the treatment of multiple sclerosis
por: Lycke, Jan, et al.
Publicado: (2020)

Autologous Hematopoietic Stem Cell Transplantation (AHSCT): An Evolving Treatment Avenue in Multiple Sclerosis
por: Mohammadi, Reihane, et al.
Publicado: (2021)

B-Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis
por: von Niederhäusern, Valentin, et al.
Publicado: (2022)

Autologous stem cell transplantation for progressive systemic sclerosis: a prospective non-interventional study from the European Society for Blood and Marrow Transplantation Autoimmune Disease Working Party
por: Henes, Joerg, et al.
Publicado: (2020)

Immunological Balance Is Associated with Clinical Outcome after Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetes
por: Malmegrim, Kelen C. R., et al.
Publicado: (2017)

The role of innate immune cells in systemic sclerosis in the context of autologous hematopoietic stem cell transplantation
por: Servaas, N. H., et al.
Publicado: (2020)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_nutcoiadi59cstt8a97ufa5avc